Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Martin Kaiser

Martin Kaiser

MD, FRCP, FRCPath
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Defining and identifying ultra-high-risk multiple myeloma 3:11
Defining and identifying ultra-high-risk multiple myeloma
Martin Kaiser • 10 Dec 2023
OPTIMUM/MUKnine: the risk of early relapse in patients with ultra high-risk multiple myeloma 2:26
OPTIMUM/MUKnine: the risk of early relapse in patients with ultra high-risk multiple myeloma
Martin Kaiser • 10 Dec 2023
The importance of genetic testing in high-risk multiple myeloma & targeted therapy 6:34
The importance of genetic testing in high-risk multiple myeloma & targeted therapy
Martin Kaiser • 27 Aug 2022
MUK Nine b update: Dara-CVRd induction plus dara-VRd consolidation for ultra-high risk NDMM and pPCL 4:08
MUK Nine b update: Dara-CVRd induction plus dara-VRd consolidation for ultra-high risk NDMM and pPCL
Martin Kaiser • 11 Dec 2021
The future of transplantation in NDMM 1:17
The future of transplantation in NDMM
Martin Kaiser • 11 Dec 2021
Is treatment discontinuation feasible for patients with myeloma with deep and durable responses? 1:40
Is treatment discontinuation feasible for patients with myeloma with deep and durable responses?
Martin Kaiser • 11 Dec 2021
Treating multiple myeloma in the UK 1:10
Treating multiple myeloma in the UK
Martin Kaiser • 11 Dec 2021
MUK Seven biomarker trial: prognostic molecular stratification in R/R MM 2:15
MUK Seven biomarker trial: prognostic molecular stratification in R/R MM
Martin Kaiser • 7 Dec 2019
Molecular therapy stratification for high-risk MM: MUK Nine b OPTIMUM 2:55
Molecular therapy stratification for high-risk MM: MUK Nine b OPTIMUM
Martin Kaiser • 7 Dec 2019
Myeloma XI: early treatment stratification and novel treatment approaches 3:14
Myeloma XI: early treatment stratification and novel treatment approaches
Martin Kaiser • 7 Dec 2019
Integrating genetic screening into treatment planning for high risk MM 3:08
Integrating genetic screening into treatment planning for high risk MM
Martin Kaiser
How does heterogeneity in TP53 activity affect MM prognosis? 1:40
How does heterogeneity in TP53 activity affect MM prognosis?
Martin Kaiser • 16 Apr 2018
Can genetic abnormalities be targeted in MM? 2:18
Can genetic abnormalities be targeted in MM?
Martin Kaiser • 19 Apr 2018
Therapeutically targeting mutations in myeloma: NF-κB, t(4;14) and BRAF 2:59
Therapeutically targeting mutations in myeloma: NF-κB, t(4;14) and BRAF
Martin Kaiser • 19 Apr 2018
MUK Nine b: OPTIMUM, paving the way to effectively treat newly diagnosed high-risk MM 3:25
MUK Nine b: OPTIMUM, paving the way to effectively treat newly diagnosed high-risk MM
Martin Kaiser • 9 Dec 2017
ASH highlights: groundbreaking results from the TEAMM trial 1:36
ASH highlights: groundbreaking results from the TEAMM trial
Martin Kaiser • 9 Dec 2017
The content of VJHemOnc is intended for healthcare professionals